Lafora progressive myoclonus epilepsy: Recent insights into cell degeneration

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 6, Issue 2, 2012, Pages 99-107

  Spuch, Carlos ^a   Ortolano, Saida ^a   Navarro, Carmen ^a  

^a University Hospital of Vigo   (Spain)

Author keywords

Brain; Brain diseases; Central nervous system; Lafora disease; Laforin; Malin; Neurodegenerative diseases

Indexed keywords

BETA CATENIN; COLLAPSIN RESPONSE MEDIATOR PROTEIN; COLLAPSIN RESPONSE MEDIATOR PROTEIN 2; GLYCOGEN SYNTHASE KINASE 3BETA; LAFORIN; MALIN; PHOSPHOPROTEIN PHOSPHATASE; PRESENILIN 1; TAU PROTEIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; WNT3A PROTEIN;

ARTICLE; AUTOSOMAL RECESSIVE DISORDER; BIOACCUMULATION; CELL INCLUSION; CLINICAL FEATURE; DISORDERS OF CARBOHYDRATE METABOLISM; EPM2A GENE; EPM2B GENE; GENE; GENE MUTATION; GLYCOGEN SYNTHESIS; HUMAN; INTELLECTUAL IMPAIRMENT; MYOCLONUS; MYOCLONUS EPILEPSY; NERVE CELL DEGENERATION; NEUROLOGIC DISEASE; NHLRC1 GENE; NONHUMAN; ONSET AGE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; TONIC CLONIC SEIZURE; VISUAL HALLUCINATION;

EID: 84861771642     PISSN: 18722148     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221412800604617     Document Type: Article

References (88)

1. Shahwan A, Farrell M, Delanty N. Progressive myoclonic epilepsies: A review of genetic and therapeutic aspects. Lancet Neurol 2005; 4: 239-48.
2. Lalioti MD, Scott HS, Genton P, Grid D, Ouazzani R, M'Rabet A, et al. A PCR amplification method reveals instability of the dodecamer repeat in progressive myoclonus epilepsy (EPM1) and no correlation between the size of the repeat and age at onset. Am J Hum Genet 1998; 62:842-7.
3. Berkovic SF, Andermann F, Carpenter S, Wolfe LS. Progressive myoclonus epilepsies: Specific causes and diagnosis. N Engl J Med 1986; 315: 296-305.
4. Norio R, Koskiniemi M. Progressive myoclonus epilepsy: Genetic and nosological aspects with special reference to 107 Finnish patients. Clin Genet 1979; 15: 382-98
5. ] Delgado-Escueta AV, Ganesh, S. Yamakawa K. Advances in the genetics of progressive myoclonus epilepsy. Am J Medical Genetics (Semin Med Genet) 2001; 106:129-38.
6. Lalioti MD, Antonarakis SE, Scott HS. The epilepsy, the protease inhibitor and the dodecamer: progressive myoclonus epilepsy, cystatin B and a 12-mer repeat expansion. Cytogenet Genome Res 2003; 100: 213-23.
7. Striano P, Zara F, Turnbull J, Girard JM, Ackerley CA, Cervasio M, et al. Typical progression of myoclonic epilepsy of the Lafora type. Nat Clin Pract Neurol 2008; 4: 106-11.
8. Larsson NG, Mar H, Tulinius T, Holme E, Oldfors A, Andersen O, et al. Segregation and Manifestations of the mtDNA tRNA'YS A'GO8344 Mutation of Myoclonus Epilepsy and Ragged-Red Fibers (MERRF) Syndrome. Am J Hum Genet 1992; 51:1201-12.
9. Satishchandra P, Sinha S. Progressive myoclonic epilepsy. Neurol India 2010; 58: 514-22.
10. [ Palmeri S, Villanova M, Malandrini A, van Diggelend OP, Huijmansd JGM, Ceuterick C, et al. Type I Sialidosis: A Clinical, Biochemical and Neuroradiological Study. Eur Neurol 2000; 43: 88-94.
11. Lafora G and Glick G. Beitrag zur histopathologie der myoklonischen epilepsie. Z Ges Neurol Psychiatr 1911; 6: 1-14.
12. Lafora GR. Uber des Vorkommen amyloider KJrperchen im innern der Ganglienzellen. Virchows Arch Path Anat 1911; 205: 95.
13. Virchow RLK. Die Cellular pathologie in ihrer Begründung auf physiologische and pathologische Gewebelehre. Hirschwald 1858.
14. Monaghan TS, Delanty N. Lafora disease. Epidemiology, pathophysiology and management. CNS drugs 2010; 24: 1-13.
15. The lafora progressive myoclonus epilepsy mutation and polymorphism database. Available on http://projects.tcag.ca/lafora/
16. ] Franceschetti S, Gambardella A, Canafoglia L, Striano P, Lohi H, Gennaro E, et al. Clinical and genetic findings in 26 Italian patients with Lafora disease. Epilepsia 2006; 47: 640-3.
17. Singh S, Suzuki T, Uchiyama A, Kumada S, Moriyama N, Hirose S, et al. Mutations in the NHLRC1 gene are the common cause for Lafora disease in the Japanese population. J Human Genet 2005; 50: 347-52.
18. Acharya JN, Satischandra P, Asha T, Shankar SK. Lafora's disease in south India: A clinical, electrophysiologic, and pathologic study. Epilepsia 1993; 34: 476-87.
19. Gomez-Abad C, Afawi Z, Korczyn AD, Misk A, Shalev SA, Spiegel R, et al. Founder effect with variable age at onset in Arab families with Lafora disease and EPM2A mutation. Epilepsia 2007; 48: 1011-4.
20. Solis MV. Lafora disease and founder effect in a small neotropical locality. Rev Biol Trop 2000; 48: 703-6.
21. Baykan B, Striano P, Gianotti S, Bebek N, Gennaro E, Gurses C, et al. Late-onset and slow progressing Lafora disease in four siblings with EPM2B mutation. Epilepsia 2005; 46: 1695-7.
22. Berkovic SF, So NK, Andermann F. Progressive myoclonus epilepsies: Clinical and neurophysiological diagnosis. J Clin Neurophysiol 1991; 8: 261-74.
23. Minassian BA. Lafora's disease: Towards a clinical, pathologic, and molecular synthesis. Pediatr Neurol 2001; 25: 21-9.
24. Vilchez D, Ros S, Cifuentes D, Pujadas L, Vallès J, García-Fojeda B, et al. Mechanism suppressing glycogen synthesis in neurons and its demise in progressive myoclonus epilepsy. Nat Neurosci 2007; 10: 1407-13.
25. Romá-Mateo C, Solaz-Fuster M del C, Gimeno-Alcañiz JV, Dukhande VV, Donderis J, Worby CA, et al. Laforin, a dual specificity phosphatise involved in Lafora disease, is phosphorylated at Ser25 by AMP-activated protein kinase. Biochem J 2011; 439: 265-75.
26. Cheng A, Zhang M, Gentry MS, Worby CA, Dixon JE, Saltiel AR. A role for AGL ubiquitination in the glycogen storage disorders of Lafora and Cori's disease. Genes Dev 2007; 21: 2399-409.
27. Worby CA, Gentry MS, Dixon JE. Malin decreases glycogen accumulation by promoting the degradation of protein targeting to glycogen (PTG). J Biol Chem 2008; 283: 4069-76.
28. Minassian BA, Lee JR, Herbrick JA, Huizenga J, Soder S, Mungall AJ, et al. Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy. Nat Genet 1998; 20: 171-4
29. [] Serratosa JM, Gomez-Garre P, Gallardo ME, Anta B, de Bernabe DB, Lindhout D, et al. A novel protein tyrosine phosphatase gene is mutated in progressive myoclonus epilepsy of the Lafora type (EPM2). Hum Mol Genet 1999; 8: 345-52.
30. Wang J, Stuckey JA, Wishart MJ, Dixon JE. A unique carbohydrate binding domain targets the lafora disease phosphatase to glycogen. J Biol Chem 2002; 277: 2377-80.
31. Dukhande VV, Sherwood AR, Gentry MS. Laforin. UCSD-Nature Molecule Pages 2010; doi:101038/mpa00003201.
32. Alonso A, Sasin J, Bottini N, Friedberg I, Friedberg I, Osterman A, et al. Protein tyrosine phosphatases in the human genome. Cell 2004; 117: 699-711.
33. Tonks NK. Protein tyrosine phosphatases: From genes, to function, to disease. Nat Rev Mol Cell Biol 2006; 7: 833-46.
34. Moohead GB, De Weyer V, Templeton G, Kerk D. Evolution of protein phosphatases in plants and animals. Biochem J 2009; 417: 401-9.
35. Gentry MS, Pace RM. Conservation of the glucan phosphatase laforin is linked to rates of molecular evolution and the glucan metabolism of the organism. BMC Evol Biol 2009; 22: 138.
36. Boraston AB, Bolam DN, Gilbert HJ, Davies GJ. Carbohydratebinding modules: Fine-tuning polysaccharide recognition. Biochem J 2004; 382: 769-81.
37. Rodriguez-Sanoja R, Oviedo N, Sanchez S. Microbial starchbinding domain. Curr Opin Microbiol 2005; 8: 260-7.
38. Cantarel BL, Coutinho PM, Rancurel C, Bernard T, Lombard V, Henrissat B. The Carbohydrate-Active EnZymes database (CAZy): An expert resource for glycogenomics. Nucleic Acids Res 2009; 37: 233-8.
39. Worby CA, Gentry MS, Dixon JE. Laforin, a dual specificity phosphatase that dephosphorylates complex carbohydrates. J Biol Chem 2006; 281: 30412-8.
40. Tagliabracci VS, Turnbull J, Wang W, Girard JM, Zhao X, Skurat AV, et al. Laforin is a glycogen phosphatase, deficiency of which leads to elevated phosphorylation of glycogen in vivo. Proc Natl Acad Sci USA 2007; 104: 19262-6.
41. Ganesh S, Agarwala KL, Ueda K, Akagi T, Shoda K, Usui T, et al. Laforin, defective in the progressive myoclonus epilepsy of Lafora type, is a dual-specificity phosphatase associated with polyribosomes. Hum Mol Genet 2000; 9: 2251-61.
42. Dukhande VV, Rogers DM, Romá-Mateo C, Donderis J, Marina A, Taylor AO, et al. Laforin, a dual specificity phosphatase involved in Lafora disease, is present mainly as monomeric form with full phosphatase activity. PLoS One 2011; 6: e24040.
43. Tagliabracci VS, Girard JM, Segvich D, Meyer C, Turnbull J, Zhao X, et al. Abnormal metabolism of glycogen phosphate as a cause for Lafora disease. J Biol Chem 2008; 283: 33816-25.
44. Tagliabracci VS, Roach PJ. Insights into the mechanism of polysaccharide dephosphorylation by a glucan phosphatise. Proc Natl Acad Sci USA 2010; 107: 15312-3.
45. Liu R, Wang L, Chen C, Liu Y, Zhou P, Wang X, et al. Laforin negatively regulates cell cycle progression through glycogen synthase kinase 3beta-dependent mechanisms. Mol Cell Biol 2008; 28: 7236-44.
46. Gentry MS, Worby CA, Dixon JE. Insights into Lafora disease: Malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin. Proc Natl Acad Sci USA 2005; 102: 8501-6.
47. Solaz-Fuster MC, Gimeno-Alcañiz JV, Ros S, Fernandez-Sanchez ME, Garcia-Fojeda B, Criado-Garcia O, et al. Regulation of glycogen synthesis by the laforin-malin complex is modulated by the AMP-activated protein kinase pathway. Hum Mol Genet 2008; 17: 667-78.
48. Fernandez-Sanchez ME, Criado-Garcia O, Heath KE, Garcia- Fojeda B, Medraño-Fernandez I, Gomez-Carre P, et al. Laforin, the dual-phosphatase responsible for Lafora disease, interacts with R5 (PTG), a regulatory subunit of protein phosphatase-1 that enhances glycogen accumulation. Hum Mol Genet 2003; 12: 3161-71.
49. Lohi H, Young EJ, Fitzmaurice SN, Rusbridge C, Chan EM, Vervoort M, et al. Expanded repeat in canine epilepsy. Science 2005; 307:81.
50. Lohi H, Ianzano L, Zhao XC, Chan EM, Turnbull J, Scherer SW, et al. Novel glycogen synthase kinase 3 and ubiquitination pathways in progressive myoclonus epilepsy. Hum Mol Genet 2005; 14: 2727-36.
51. Sharma J, Mulherkar S, Mukherjee D, Jana NR. Malin regulates Wnt signaling pathway through degradation of dishevelled 2. J Biol Chem 2012; doi:10.1074/jbc.M111.315135 jbc.M111.315135.
52. Mittal S, Dubev D, Yamakawa K, Ganesh S. Lafora disease proteins malin and laforin are recruited to aggresomes in response to proteasomal impairment. Hum Mol Genet 2007; 16: 753-62.
53. Johnston JA, Ward CL, Kopito RR. Aggresomes: A cellular response to misfolded proteins. J Cell Biol 1998; 143: 1883-98.
54. Garyali P, Siwach P, Singh PK, Puri R, Mittal S, Sengupta S, et al. The malin-laforin complex suppresses the cellular toxicity of misfolded proteins by promoting their degradation through the ubiquitin-proteasome system. Hum Mol Genet 2009; 18: 688-700.
55. Ballinger CA, Connel P, Wu Y, Thompson LJ, Yin LY, Patterson C. Identification of CHIP, a novel tetratricopeptide repeatcontaining protein that interacts with heat shock proteins and negatively regulates chaperone functions. Mol Cell Biol 1999; 19: 4535-45.
56. Murata S, Chiba T, Tanaka K. CHIP: A quality-control E3 ligase collaborating with molecular chaperones. Int J Biochem Cell Biol 2003; 35: 572-8.
57. Inestrosa NC, Arenas E. Emerging roles of Wnts in the adult nervous system. Nat rev Neurosci 2010; 11: 77-86.
58. Bassuk AG, Wallace RH, Buhr A, Buller AR, Afawi Z, Shimojo M, et al. A homozygous mutation in human PRICKLE1 causes an autosomal-recessive progressive myoclonus epilepsy-ataxia syndrome. Am J Hum Genet 2008; 83: 572-81.
59. Roach PJ, Depaoli-Roach AA, Hurley TD, Tagliabracci VS. Glycogen and its metabolism: Some new developments and old themes. Biochem J 2012; 441: 763-87.
60. Kaidanovich-Beilin O, Woodgett JR. GSK-3: Functional insights from cell biology and animal models. Front Mol Neurosci 2011; 4: 40.
61. Melendez R, Meléndez-Hevia E, Cascante M. How did glycogen structure evolve to satisfy the requirement for rapid mobilization of glucose? A problem of physical constraints in structure building. J Mol Evol 1997; 45: 446-55.
62. Shearer J, Graham TE. Novel aspects of skeletal muscle glycogen and its regulation during rest and exercise. Exerc Sport Sci Rev 2004; 32: 120-6.
63. Fontana JD. The presence of phosphate in glycogen. FEBS Lett 1980; 109: 85-92.
64. Lomako J, Lomako WM, Kirkman BR, Whelan WJ. The role of phosphate in muscle glycogen. Biofactors 1994; 4: 167-71.
65. Lomako J, Lomako WM, Whelan WJ, Marchase RB. Glycogen contains phosphodiester groups that can be introduced by UDPglucose: Glycogen glucose 1phosphotransferase. FEBS Lett 1993; 329: 263-7.
66. Schnabel R, Seitelberger F. Histophysical and histochemical investigations of myoclonus bodies. Pathol Eur 1968; 3: 218-26.
67. Criado O, Aguado C, Gayarre J, Duran-Trio L, Garcia-Cabrero AM, Vernia S, et al. Lafora bodies and neurological defects in malin-defiient mice correlate with impaired autophagy. Hum Mol Genet 2011; doi: 10.1093/hmg/ddr590.
68. Liu Y, Wang Y, Wu C, Liu Y, Zheng P. Dimerization of laforin is required for its optimal phosphatase activity, regulation of GSK3beta phosphorylation, and Wnt signaling. J Biol Chem 2006; 281: 34768-74.
69. Ganesh S, Delgado-Escueta AV, Sakamoto T, Avila MR, Machado-Salas J, Hoshii Y, et al. Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice. Hum Mol Genet 2002; 11: 1251-62.
70. Minassian BA. Progressive myoclonus epilepsy with polyglucosan bodies: Lafora disease. Adv Neurol 2002; 89: 199-210.
71. Raben N, Danon M, Lu N, Lee E, Shliselfeld L, Skurat AV, et al. Surprises of genetic engineering: A possible model of polyglucosan body disease. Neurology 2001; 56: 1739-45.
72. Wang W, Lohi H, Skurat AV, DePaoli-Roach AA, Minassian BA, Roach PJ, et al. Glycogen metabolism in tissues from a mouse model of Lafora disease. Arch Biochem Biophys 2007; 457: 264-9.
73. Ganesh S, Tsurutani N, Suzuki T, Hoshii Y, Ishihara T, DelgadoEscueta AV, et al. The carbohydrate-binding domain of Lafora disease protein targets Lafora polyglucosan bodies. Biochem Biophys Res Commun 2004; 313:1101-9.
74. Wang W, Roach PJ. Glycogen and related polysaccharides inhibit the laforin dual-specificity protein phosphatase. Biochem Biophys Res Commun 2004; 325: 726-30.
75. Brown AM, Ransom BR. Astrocyte glycogen and brain energy metabolism. Glia 2007; 55: 1263-71.
76. Holzbaur EL, Scherer SS. Microtubules, axonal transport and neuropathy. N Engl J Med 2011; 365: 2330-2.
77. Paige J. Redefining tumour suppressor genes: Exceptions to the two-hit hypothesis Cell Mol Life Sci 2003; 60: 2147-63.
78. Noviello C, Courjal F, Theillet C. Loss of heterozygosity on the long arm of chromosome 6 in breast cancer: Possibly four regions of deletion. Clin Cancer Res 1996; 2:1601-106.
79. Wang Y, Liu Y, Wu C, Zhang H, Zheng X, Zheng Z, et al. Epm2a suppresses tumor growth in an immunocompromised host by inhibiting Wnt signaling. Cancer Cell 2006; 10:179-90.
80. Puri R, Suzuki T, Yamakawa K, Ganesh S. Hyperphosphorylation and aggregation of Tau in laforin-deficient mice, an animal model for Lafora disease. J Biol Chem 2009; 284: 22657-63.
81. Scherer, S., Minassian, B., Delgado-Escueta, A., Rouleu, G. Lafora's disease gene. US6825328 (2004).
82. Scherer, S., Minassian, B. Lafora's disease gene. WO2005012526 (2005), US20070184442 (2007) & US2010009346 (2010).
83. Kazuhiro, Y., Delgado-Escueta, A. Perfect length sequence of human lafora type epilepsy causing gene and use of mutation thereof. JP2001299350 (2001)
84. Wang, H., Zhang, Y. Ubiquitin E3 ligase. US7923219 (2011)
85. Yoshida, H., Hanai, N., Furuya, A. Anti-lafora body monoclonal antibody. US4962032 (1990).
86. Mandel, A., Bolton, A., Nolan, Y. Treatment of ubiquitinproteosome system dysfunction related disorders. WO2007131329 (2007).
87. Zhuandwu, L., Hue, M. Methods and kits for determining ubiquitin protein ligase (E3) activity. US2006088901 (2006).
88. Pan, Z., Yang L., Yin, W., Yan, L. Laforin expression in diagnosis and treatment of cancer and other diseases. WO2006052911 (2006).